Therapeutic Research Progress Of PD-1/PD-L1 And Non-small Cell Lung Cancer

The limited intervenes lead to a undesirable prognosis to patients with lung cancer.In recent years,immune therapy has become the new a im in the treatment of non-small cell lung cancer except surgery,radiot herapy,chemotherapy and so on.The immune checkpoints represented by programmed death-1 and programmed death-1 ligand have an significa nt influence on the development of cancer,indicating the relationship bet ween the inhibitors like anti-PD-1/PD-L1 monoclonal antibody and surv ival,and the potential to PD-L1 as biomarker for curative effect.At pres ent,Nivolumab and Perbrolizumab,the two pioneers,have crteated another way focusing on non-small cell lung cancer.The FDA approved pembr olizumab as the first-line and the two aboved-mentioned immune inhibit ors as the second-line treatment for patients suffering non-small cell lun g cancer.This article summarizes the signal pathway of PD-1/PD-L1,me chanism of anti-PD-1 antibody in non-small cell lung cancer,as well as its clinical current and future direction.